# NCT04634539 (NCT04634539)

> Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04634539
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Jun Gong, MD
- Conditions: Advanced Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma
- Interventions: Gemcitabine; Nab-paclitaxel; L-glutamine
- Enrollment: 18
- Primary outcome: Recommended phase II dose (RP2D) of combination gemcitabine, nab-paclitaxel, and L-glutamine in treatment-naive metastatic pancreatic cancer.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04634539